Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000687544 | SCV000815117 | pathogenic | Lowe syndrome | 2018-06-09 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change impairs binding to APPL1 and disrupts normal endosomal co-localization with EGFP (PMID: 17765681). In addition, experimental studies on fibroblasts from an individual carrying this missense change showed a reduced amount of OCRL protein and lower PI(4,5)P2-phosphatase activity (PMID: 21031565). This variant has been observed to be hemizygous in individuals affected with Lowe syndrome (PMIID: 10923037, 21031565). This variant is also known as p.Ala780Pro in the literature. This variant is not present in population databases (ExAC no frequency). This sequence change replaces alanine with proline at codon 797 of the OCRL protein (p.Ala797Pro). The alanine residue is highly conserved and there is a small physicochemical difference between alanine and proline. |